A study of a combination of 2 immunotherapy drugs vs. 1 immunotherapy drug for patients at high risk for recurrence of melanoma

UVA Tracking #
HSR200243
Principal Investigator
Elizabeth M Gaughan
Contact
Adela Mahmutovic
Contact Email
Contact Phone
434.982.6914
Official Trial Title
A Phase 3, Randomized, Open-label Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined with Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence (PIVOT-12)
Study Description

The UVA Cancer Center seeks adults ages 18 and over with melanoma for a clinical trial. The purpose of this study is to evaluate a combined treatment of 2 different immunotherapy drugs (Bempegaldesleukin, Nivolumab) vs Nivolumab alone after complete resection of melanoma. Disease response and good and bad effects of the combination of the two drugs vs 1 drug will be studied as part of this study.
Treatment will be up to 1 year, followed by a longer term follow-up via a clinic visit or phone call to keep track of how you’re doing. Study specific tests will be provided at no cost to you.

Additional information can be found here: https://clinicaltrials.gov/ct2/show/NCT04410445

Compensation

No Compensation